579 related articles for article (PubMed ID: 33170748)
1. Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.
Sonnenschein SF; Grace A
Expert Opin Ther Targets; 2021 Jan; 25(1):15-26. PubMed ID: 33170748
[No Abstract] [Full Text] [Related]
2. A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis.
Squires RF; Saederup E
Neurochem Res; 1991 Oct; 16(10):1099-111. PubMed ID: 1686635
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
Howes OD; Egerton A; Allan V; McGuire P; Stokes P; Kapur S
Curr Pharm Des; 2009; 15(22):2550-9. PubMed ID: 19689327
[TBL] [Abstract][Full Text] [Related]
4. New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways.
Perez SM; Lodge DJ
Drug Des Devel Ther; 2014; 8():887-96. PubMed ID: 25061280
[TBL] [Abstract][Full Text] [Related]
5. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia.
Lodge DJ; Grace AA
Trends Pharmacol Sci; 2011 Sep; 32(9):507-13. PubMed ID: 21700346
[TBL] [Abstract][Full Text] [Related]
6. The glutamate hypothesis of schizophrenia: neuroimaging and drug development.
Egerton A; Stone JM
Curr Pharm Biotechnol; 2012 Jun; 13(8):1500-12. PubMed ID: 22283750
[TBL] [Abstract][Full Text] [Related]
7. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
[TBL] [Abstract][Full Text] [Related]
8. Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.
Gomes FV; Grace AA
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922888
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol modulation of hippocampal glutamate in early psychosis.
O'Neill A; Annibale L; Blest-Hopley G; Wilson R; Giampietro V; Bhattacharyya S
J Psychopharmacol; 2021 Jul; 35(7):814-822. PubMed ID: 33860709
[TBL] [Abstract][Full Text] [Related]
10. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
[TBL] [Abstract][Full Text] [Related]
11. Anterior Hippocampal-Cortical Functional Connectivity Distinguishes Antipsychotic Naïve First-Episode Psychosis Patients From Controls and May Predict Response to Second-Generation Antipsychotic Treatment.
Blessing EM; Murty VP; Zeng B; Wang J; Davachi L; Goff DC
Schizophr Bull; 2020 Apr; 46(3):680-689. PubMed ID: 31433843
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic-evoked dopamine supersensitivity.
Servonnet A; Samaha AN
Neuropharmacology; 2020 Feb; 163():107630. PubMed ID: 31077727
[TBL] [Abstract][Full Text] [Related]
13. Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy.
Włodarczyk A; Szarmach J; Cubała WJ; Wiglusz MS
Psychiatr Danub; 2017 Sep; 29(Suppl 3):345-348. PubMed ID: 28953788
[TBL] [Abstract][Full Text] [Related]
14. Schizophrenia, psychosis, and the basal ganglia.
Busatto GF; Kerwin RW
Psychiatr Clin North Am; 1997 Dec; 20(4):897-910. PubMed ID: 9443356
[TBL] [Abstract][Full Text] [Related]
15. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.
de Bartolomeis A; Fiore G; Iasevoli F
Curr Pharm Des; 2005; 11(27):3561-94. PubMed ID: 16248808
[TBL] [Abstract][Full Text] [Related]
16. [A biochemical theory of schizophrenia].
Kornhuber HH; Kornhuber J; Kim JS; Kornhuber ME
Nervenarzt; 1984 Nov; 55(11):602-6. PubMed ID: 6151120
[TBL] [Abstract][Full Text] [Related]
17. Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study.
Hasan A; Wobrock T; Grefkes C; Labusga M; Levold K; Schneider-Axmann T; Falkai P; Müller H; Klosterkötter J; Bechdolf A
Biol Psychiatry; 2012 Nov; 72(9):744-51. PubMed ID: 22502988
[TBL] [Abstract][Full Text] [Related]
18. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.
Karam CS; Ballon JS; Bivens NM; Freyberg Z; Girgis RR; Lizardi-Ortiz JE; Markx S; Lieberman JA; Javitch JA
Trends Pharmacol Sci; 2010 Aug; 31(8):381-90. PubMed ID: 20579747
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
Goff DC; Coyle JT
Am J Psychiatry; 2001 Sep; 158(9):1367-77. PubMed ID: 11532718
[TBL] [Abstract][Full Text] [Related]
20. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.
Huang M; Li Z; Dai J; Shahid M; Wong EH; Meltzer HY
Neuropsychopharmacology; 2008 Nov; 33(12):2934-45. PubMed ID: 18418367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
